Loss of XIST LncRNA Unlocks Stemness and Cellular Plasticity in Ovarian Cancer

Overview

Journal Proc Natl Acad Sci U S A

Specialty Science

Date 2024 Nov 15

PMID 39546568

Authors

Ikrame Naciri

Minzhi Liang

Ying Yang

Heather Karner

Benjamin Lin

Maria De Lourdes Andrade Ludena

Eric A Hanse

Alfredo Lebron

Olga V Razorenova

Dequina Nicholas

Mei Kong

Sha Sun

Affiliations

Soon will be listed here.

Abstract

Plasticity, a key hallmark of cancer, enables cells to transition into different states, driving tumor heterogeneity. This cellular plasticity is associated with cancer progression, treatment resistance, and relapse. Cancer stem cells (CSCs) play a central role in this process, yet the molecular factors underlying cancer cell stemness remain poorly understood. In this study, we explored the role of XIST (X-inactive specific transcript) long noncoding RNA in ovarian cancer stemness and plasticity through in silico and in vitro analyses. We found that XIST is significantly down-regulated in ovarian tumors, with low XIST expression linked to a higher stemness index and lower overall survival. Knocking down XIST in ovarian cancer cells enhanced stemness, particularly increasing mesenchymal-like CSCs, and under hypoxic conditions, it promoted epithelial-like CSC markers. Our findings suggest that XIST loss leads to CSC enrichment and cellular plasticity in ovarian cancer, pointing to potential therapeutic targets for patients with low XIST expression.

Citing Articles

Loss of XIST lncRNA unlocks stemness and cellular plasticity in ovarian cancer.

Naciri I, Liang M, Yang Y, Karner H, Lin B, De Lourdes Andrade Ludena M Proc Natl Acad Sci U S A. 2024; 121(47):e2418096121.

PMID: 39546568 PMC: 11588085. DOI: 10.1073/pnas.2418096121.

References

Keith B, Simon M . Hypoxia-inducible factors, stem cells, and cancer. Cell. 2007; 129(3):465-72. PMC: 3150586. DOI: 10.1016/j.cell.2007.04.019. View

Payer B, Lee J . X chromosome dosage compensation: how mammals keep the balance. Annu Rev Genet. 2008; 42:733-72. DOI: 10.1146/annurev.genet.42.110807.091711. View

Coan M, Haefliger S, Ounzain S, Johnson R . Targeting and engineering long non-coding RNAs for cancer therapy. Nat Rev Genet. 2024; 25(8):578-595. DOI: 10.1038/s41576-024-00693-2. View

Yildirim E, Kirby J, Brown D, Mercier F, Sadreyev R, Scadden D . Xist RNA is a potent suppressor of hematologic cancer in mice. Cell. 2013; 152(4):727-42. PMC: 3875356. DOI: 10.1016/j.cell.2013.01.034. View

Ma H, Tian T, Cui Z . Targeting ovarian cancer stem cells: a new way out. Stem Cell Res Ther. 2023; 14(1):28. PMC: 9926632. DOI: 10.1186/s13287-023-03244-4. View

Huarte M . The emerging role of lncRNAs in cancer. Nat Med. 2015; 21(11):1253-61. DOI: 10.1038/nm.3981. View

Patel A, Yanai I . A developmental constraint model of cancer cell states and tumor heterogeneity. Cell. 2024; 187(12):2907-2918. PMC: 11256907. DOI: 10.1016/j.cell.2024.04.032. View

Sadagopan A, Nasim I, Li J, Achom M, Zhang C, Viswanathan S . Somatic XIST activation and features of X chromosome inactivation in male human cancers. Cell Syst. 2022; 13(11):932-944.e5. DOI: 10.1016/j.cels.2022.10.002. View

Hallas-Potts A, Dawson J, Herrington C . Ovarian cancer cell lines derived from non-serous carcinomas migrate and invade more aggressively than those derived from high-grade serous carcinomas. Sci Rep. 2019; 9(1):5515. PMC: 6445084. DOI: 10.1038/s41598-019-41941-4. View

10.

Beaufort C, Helmijr J, Piskorz A, Hoogstraat M, Ruigrok-Ritstier K, Besselink N . Ovarian cancer cell line panel (OCCP): clinical importance of in vitro morphological subtypes. PLoS One. 2014; 9(9):e103988. PMC: 4167545. DOI: 10.1371/journal.pone.0103988. View

11.

Hanahan D . Hallmarks of Cancer: New Dimensions. Cancer Discov. 2022; 12(1):31-46. DOI: 10.1158/2159-8290.CD-21-1059. View

12.

Fan H, Atiya H, Wang Y, Pisanic T, Wang T, Shih I . Epigenomic Reprogramming toward Mesenchymal-Epithelial Transition in Ovarian-Cancer-Associated Mesenchymal Stem Cells Drives Metastasis. Cell Rep. 2020; 33(10):108473. PMC: 7747301. DOI: 10.1016/j.celrep.2020.108473. View

13.

Loh J, Ma S . Hallmarks of cancer stemness. Cell Stem Cell. 2024; 31(5):617-639. DOI: 10.1016/j.stem.2024.04.004. View

14.

Liu S, Yang J, Cao D, Shen K . Identification of differentially expressed long non-coding RNAs in human ovarian cancer cells with different metastatic potentials. Cancer Biol Med. 2014; 10(3):138-41. PMC: 3860336. DOI: 10.7497/j.issn.2095-3941.2013.03.003. View

15.

Chai C, Liang L, Mikkelsen N, Wang W, Zhao W, Sun C . Single-cell transcriptome analysis of epithelial, immune, and stromal signatures and interactions in human ovarian cancer. Commun Biol. 2024; 7(1):131. PMC: 10817929. DOI: 10.1038/s42003-024-05826-1. View

16.

Strauss R, Li Z, Liu Y, Beyer I, Persson J, Sova P . Analysis of epithelial and mesenchymal markers in ovarian cancer reveals phenotypic heterogeneity and plasticity. PLoS One. 2011; 6(1):e16186. PMC: 3021543. DOI: 10.1371/journal.pone.0016186. View

17.

Mattick J, Amaral P, Carninci P, Carpenter S, Chang H, Chen L . Long non-coding RNAs: definitions, functions, challenges and recommendations. Nat Rev Mol Cell Biol. 2023; 24(6):430-447. PMC: 10213152. DOI: 10.1038/s41580-022-00566-8. View

18.

Chaligne R, Popova T, Mendoza-Parra M, Saleem M, Gentien D, Ban K . The inactive X chromosome is epigenetically unstable and transcriptionally labile in breast cancer. Genome Res. 2015; 25(4):488-503. PMC: 4381521. DOI: 10.1101/gr.185926.114. View

19.

Naciri I, Andrade-Ludena M, Yang Y, Kong M, Sun S . An emerging link between lncRNAs and cancer sex dimorphism. Hum Genet. 2023; 143(7):831-842. PMC: 11176266. DOI: 10.1007/s00439-023-02620-7. View

20.

Huang R, Zhu L, Zhang Y . XIST lost induces ovarian cancer stem cells to acquire taxol resistance via a KMT2C-dependent way. Cancer Cell Int. 2020; 20:436. PMC: 7487955. DOI: 10.1186/s12935-020-01500-8. View